Bank of New York Mellon
BHVN

Bank of New York Mellon’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bank of New York Mellon’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000,497
Closed -$151M – 4649
2022
Q3 		$151M Sell
1,000,497
-14,912
-1% -$2.21M 0.04% 442
2022
Q2 		$148M Sell
1,015,409
-139,545
-12% -$17.8M 0.03% 460
2022
Q1 		$137M Sell
1,154,954
-44,441
-4% -$5.54M 0.03% 541
2021
Q4 		$165M Sell
1,199,395
-51,048
-4% -$6.49M 0.03% 487
2021
Q3 		$174M Buy
1,250,443
+18,715
+2% +$2.34M 0.03% 461
2021
Q2 		$120M Buy
1,231,728
+44,535
+4% +$3.61M 0.02% 622
2021
Q1 		$81.1M Buy
1,187,193
+375,612
+46% +$30.4M 0.02% 812
2020
Q4 		$69.6M Buy
811,581
+13,117
+2% +$1.11M 0.02% 835
2020
Q3 		$51.9M Buy
798,464
+5,903
+0.7% +$387K 0.01% 893
2020
Q2 		$57.9M Buy
792,561
+91,467
+13% +$4.87M 0.02% 798
2020
Q1 		$23.9M Buy
701,094
+149,558
+27% +$6.84M 0.01% 1187
2019
Q4 		$30M Sell
551,536
-10,206
-2% -$505K 0.01% 1311
2019
Q3 		$23.4M Buy
561,742
+16,148
+3% +$682K 0.01% 1433
2019
Q2 		$23.9M Buy
545,594
+383,594
+237% +$21.6M 0.01% 1457
2019
Q1 		$8.34M Buy
162,000
+24,538
+18% +$1.06M ﹤0.01% 2065
2018
Q4 		$5.08M Sell
137,462
-2,229
-2% -$80.4K ﹤0.01% 2279
2018
Q3 		$5.25M Sell
139,691
-2,071
-1% -$76.2K ﹤0.01% 2384
2018
Q2 		$5.6M Buy
141,762
+20,364
+17% +$646K ﹤0.01% 2332
2018
Q1 		$3.13M Buy
121,398
+78,477
+183% +$2.35M ﹤0.01% 2581
2017
Q4 		$1.16M Sell
42,921
-19,834
-32% -$546K ﹤0.01% 3156
2017
Q3 		$2.35M Buy
62,755
+10,398
+20% +$315K ﹤0.01% 2753
2017
Q2 		$1.31M Buy
+52,357
New +$1.21M ﹤0.01% 3094

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Bank of New York Mellon's BHVN Position: Q4 2022 in Review

Bank of New York Mellon sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,000,497 shares — an estimated $151M sold.

Bank of New York Mellon first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $174M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Bank of New York Mellon reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 1,000,497 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $151M.
  • Bank of New York Mellon first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Bank of New York Mellon's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $174M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.